Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Equity Ratio (2016 - 2025)

Viking Therapeutics' Equity Ratio history spans 12 years, with the latest figure at 0.89 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 7.87% year-over-year to 0.89; the TTM value through Dec 2025 reached 0.89, down 7.87%, while the annual FY2025 figure was 0.89, 7.87% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.89 at Viking Therapeutics, down from 0.96 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.98 in Q1 2025 and bottomed at 0.86 in Q4 2022.
  • The 5-year median for Equity Ratio is 0.95 (2021), against an average of 0.94.
  • The largest annual shift saw Equity Ratio fell 10.02% in 2022 before it rose 9.65% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.96 in 2021, then dropped by 10.02% to 0.86 in 2022, then increased by 9.65% to 0.95 in 2023, then rose by 2.5% to 0.97 in 2024, then dropped by 7.87% to 0.89 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Equity Ratio are 0.89 (Q4 2025), 0.96 (Q3 2025), and 0.96 (Q2 2025).